We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCRX
Cyprotex PLC
14 July 2015
Cyprotex launches new chemPK(TM) workflow solution to predict human pharmacokinetics directly from chemical structure
14th July, 2015;
Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of its new predictive modelling solution, chemPK(TM) , which predicts human pharmacokinetics directly from chemical structure. Pharmacokinetics is defined as the study of the concentration of drug in the body over time, and is based on the absorption, distribution, metabolism and excretion of a drug.
Our new chemPK(TM) solution has been developed by Cyprotex's Scientific Computing Team using PBPK (physiologically based pharmacokinetic) predictive modelling. Cyprotex have considerable expertise in this technique, having previously developed and launched the proprietary modelling software, Cloe(R) PK and Cloe(R) HIA. chemPK(TM) is a virtual screening tool meaning that it can be employed before chemical synthesis of a molecule and does not require any data inputs. This provides significant cost benefits and can be used as an early stage filter for directing chemistry and prioritising in vitro screening taking account of the predicted human pharmacokinetics.
chemPK(TM) is unique in that the model has been optimised directly on human clinical data, and so provides a more robust approach as compared to alternative models that use QSAR (quantitative structure activity relationship)-based methods for predicting their input parameters. chemPK(TM) is implemented as a collection of nodes for the widely used KNIME workflow management platform, enabling its use in either desktop or server environments, and facilitating its interaction with many other cheminformatics, analytics and modelling tools.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'Our new chemPK(TM) solution provides significant advantages over existing products in the market. It will provide our customers with an insight into the expected exposure of a molecule in the human body at an early stage enabling them to only synthesise compounds with the best chance of success.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505 100 Dr Anthony Baxter, Chief Executive ir@cyprotex.com Officer www.cyprotex.com John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496 Cyprotex) 3000 Shaun Dobson shaun.dobson@n1singer.com Jen Boorer jennifer.boorer@n1singer.com www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRARJMTTMBBBBTA
1 Year Cyprotex Chart |
1 Month Cyprotex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions